Amylin Pharmaceuticals, Inc. and Eli Lilly and Company have agreed in principle to the terms of ajoint supply agreement for an exenatide once weekly pen device. Separately,the companies announced that they have initiated a phase 1/2 clinical study toexamine a new exenatide once weekly suspension formulation. Exenatide once weekly is an investigational diabetes therapy that isinjected subcutaneously once a week and is currently in phase 3 development.Exenatide is also the active ingredient in twice daily BYETTA(R) (exenatide)injection, currently available in the U.S. and in many countries worldwide forpeople with type 2 diabetes who are unable to achieve good glycemic controlwith common oral therapies.
